Table 1 Characteristics of the patients according to the etiology of the liver disease (CHB and CHC).

From: MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C

N, patients

Chronic hepatitis B

Chronic Hepatitis C

N total = 58

F0/F1/F2

N total = 44

F3/F4

p value

N total = 84

F0/F1/F2

N total = 94

F3/F4

p value

Gender: male/female, n (%)

58

50 (86.2)/8 (13.8)

44

37 (84.1)/7 (15.9)

0.78

84

41 (48.8)/43 (51.2)

94

64 (68.1)/30 (31.9)

0.01

Age, years (median, IQ)

58

42 [30.25; 52.5]

43

42 [33.5; 47]

0.83

84

49 [43; 55]

92

49 [44; 54]

0.94

BMI, kg.m−2 (median, IQ)

50

25.1 [23.1; 27.5]

41

25.9 [23.2; 28.3]

0.43

70

24.6 [22.2; 27.8]

64

25.8 [24.2; 28.8]

0.045

ALT, IU/L (median, IQ)

58

66 [49; 120.8]

44

78.5 [54.8; 161]

0.50

82

79.5 [57.2; 101.5]

92

119 [65.5; 154.5]

0.0002

AST, IU/L (median, IQ)

58

40.5 [34.3; 62.8]

44

59.5 [36; 131]

0.047

82

47 [36.5; 62.8]

91

77 [52; 112]

<0.0001

ALP, IU/L (median, IQ)

57

43 [27; 63]

40

94 [44.5; 181.5]

0.0002

82

65 [52; 78.8]

88

80 [60.8; 107]

<0.0001

GGT, IU/L (median, IQ)

55

15 [11; 17]

43

18 [14.5; 24.5]

0.001

82

44.5 [26; 78.5]

90

96 [58.25; 156]

<0.0001

Platelets, x103/mm3(median, IQ)

58

196.5 [162; 234.8]

43

156 [135; 192]

0.0003

78

230 [188; 263]

83

172 [120.5; 209]

<0.0001

Cholesterol, mmol/L (median, IQ)

 

NA

 

NA

 

68

4.75 [4.3; 5.5]

60

4.2 [3.6; 4.7]

<0.0001

Triglycerides, mmol/L (median, IQ)

50

0.9 [0.6; 1.1]

32

1.0 [0.7; 1.7]

0.035

67

0.94 [0.7; 1.1]

59

0.92 [0.7; 1.4]

0.44

Glycemia, mmol/L (median, IQ)

51

4.8 [4.3; 5.1]

35

5.1 [4.5; 5.9]

0.027

71

4.9 [4.5; 5.4]

71

5.4 [4.8; 6.1]

0.0003

Total bilirubin, μmol/L (median, IQ)

22

10.1 [6.3; 13.8]

6

16,9 [13.6; 39.5]

0.031

79

12 [9; 15]

90

14 [10; 18]

0.01

Albumin, g/L (median, IQ)

57

47.2 [44; 49.4]

41

44.4 [41.4; 47.3]

0.002

69

45.4 [44; 48]

70

45.1 [43; 47.8]

0.26

Viral Loads, logUI/mL (median, IQ)

58

6.2 [4.3; 7.3]

42

5.9 [4.1; 7.2]

0.27

52

5.6 [5.2; 6.1]

59

5.9 [5.3; 6.3]

0.10

Necroinflammatory activity, n (%)

58

 

44

 

0.016

83

 

89

 

0.001

None (A0)

 

4 (6.9)

 

1 (2.3)

  

10 (11.9)

 

5 (5.3)

 

Mild (A1)

 

33 (56.9)

 

18 (40.9)

  

58 (69.0)

 

44 (46.8)

 

Moderate (A2)

 

20 (34.5)

 

20 (45.4)

  

14 (16.7)

 

35 (37.2)

 

Severe (A3)

 

1 (1.7)

 

5 (11.4)

  

1 (1.2)

 

5 (5.3)

 

NA

 

0

 

0

  

1 (1.2)

 

5 (5.3)

 

Steatosis Grades, n (%)

58

 

44

 

0.26

82

 

84

 

0.02

0

 

35 (60.3)

 

22 (50)

  

37 (44.05)

 

23 (24.5)

 

1

 

15 (25.9)

 

12 (27.3)

  

27 (32.14)

 

24 (25.5)

 

2

 

5 (8.6)

 

8 (18.1)

  

15 (17.86)

 

28 (29.8)

 

3

 

0 (0)

 

1 (2.3)

  

3 (3.57)

 

9 (9.6)

 

NA

 

3 (5.2)

 

1 (2.3)

  

2 (2.38)

 

10 (10.6)

 

HCV genotypes, n (%)

 

—

 

—

 

78

 

88

 

0.007

1

 

—

 

—

  

40 (47.6)

 

48 (51.1)

 

2

 

—

 

—

  

11 (13.1)

 

2 (2.1)

 

3

 

—

 

—

  

11 (13.1)

 

17 (18.1)

 

4

 

—

 

—

  

11 (13.1)

 

21 (22.3)

 

5

 

—

 

—

  

3 (3.6)

 

0 (0)

 

6

 

—

 

—

  

1 (1.2)

 

0 (0)

 

NA

 

—

 

—

  

7 (8.3)

 

6 (6.4)

 
  1. AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphate; BMI, Body mass index; GGT, Gamma-glutamyltranspeptidase, IQ: Interquartile range, NA: Not available. Clinical parameters are expressed as median and interquartile range (IQ), unless indicated differentially. Differences between chronic hepatitis B and C patients were evaluated with the Fisher’s exact (qualitative variables) and the Wilcoxon rank-sum tests (continuous variables).
Back to article page